3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
70
Neoplasm Metastasis
20
Rectal Neoplasms
19
Colonic Neoplasms
17
Neoplasms
11
Cholangiocarcinoma
7
Carcinoma, Non-Small-Cell Lung
7
Head and Neck Neoplasms
6
Esophageal Neoplasms
6
Breast Neoplasms
6
Carcinoma, Squamous Cell
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Colorectal Cancer Metastatic
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Fallopian Tube Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Serotonin Syndrome
1
Salivary Gland Malignancy
1
Interventions
Fulvestrant
2
ruxolitinib
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Gels
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Exanthema
×
Panitumumab
×
Clear all
NCT00332163
2016-02-23
STEPP
Amgen
Phase 2
Completed
95 enrolled
23 charts